INSMED Inc: directors' dealings · United States · SEC (Form 4)

About INSMED Inc

Insmed Inc. (NASDAQ: INSM) is a United States-based biopharmaceutical company listed on the NASDAQ market, with headquarters in Bridgewater, New Jersey, United States. For French, Belgian, and Swiss investors, the investment case is built around a focused specialty-biopharma model: Insmed aims to develop first-in-class and best-in-class therapies for serious diseases, particularly in areas of high unmet medical need. Rather than operating as a broad diversified pharmaceutical group, the company positions itself as a targeted innovator in respiratory disease, immunology and inflammation, and selected rare-disease opportunities. Insmed’s corporate history is layered. The company traces its roots back to 1988, when it was founded in Charlottesville, Virginia, as a private company initially focused on diabetes medicines. Its modern shape was later formed through strategic combination and pipeline expansion, including a major 2010 business combination with Transave, which had been developing inhaled pulmonary medicines. The company expanded its footprint over time, opening a global headquarters in Bridgewater in 2019 and building research presence in the United States and internationally, including Europe and Japan. That evolution matters because it shows a business that has moved from early-stage development into a more commercial biopharma platform. Operationally, Insmed’s portfolio centers on three major therapeutic pillars: respiratory, immunology & inflammation, and neuro & other rare diseases. Its commercial base includes ARIKAYCE® (amikacin liposome inhalation suspension), a differentiated inhaled treatment, and BRINSUPRI® (brensocatib), which was launched commercially in the United States in 2025 for non-cystic fibrosis bronchiectasis. The pipeline also includes TPIP (treprostinil palmitil inhalation powder) in pulmonary arterial hypertension and other pulmonary indications, along with additional earlier-stage programs across the broader platform. From a competitive standpoint, Insmed is best viewed as a specialty biotech rather than a large-cap pharma peer. Its advantages come from clinical differentiation, an addressable market with significant unmet need, and the ability to build value around a relatively small number of high-impact assets. At the same time, that concentration increases execution risk: pipeline readouts, regulatory decisions, commercialization momentum, and safety data can all have an outsized effect on valuation. Recent developments are especially relevant. In February 2026, Insmed reported full-year 2025 revenue of $606.4 million and ended 2025 with approximately $1.4 billion in cash, cash equivalents, and marketable securities. Management also said it expects at least $1 billion in full-year 2026 BRINSUPRI revenue and reaffirmed 2026 ARIKAYCE guidance of $450 million to $470 million. The company highlighted continued progress in TPIP and other pipeline assets. However, in December 2025, Insmed disclosed that the Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps missed both primary and secondary endpoints, and the program was discontinued in that indication. That mix of commercial traction and clinical volatility is typical of a developing biotech and should remain central to any investment analysis.